作者: Katherine V. Houser , Lisa Gretebeck , Tianlei Ying , Yanping Wang , Leatrice Vogel
关键词:
摘要: With >1600 documented human infections with Middle East respiratory syndrome coronavirus (MERS-CoV) and a case fatality rate of approximately 36%, medical countermeasures are needed to prevent limit the disease. We examined in vivo efficacy monoclonal antibody m336, which has high neutralizing activity against MERS-CoV vitro. m336 was administered rabbits intravenously or intranasally before infection MERS-CoV. Prophylaxis resulted reduction pulmonary viral RNA titers by 40-9000-fold, compared an irrelevant control little no inflammation antigen detected. This protection supports further clinical development m336.